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The inﬂammatory response mediated by the immune system is the major cause of hepatitis B virus
(HBV)-associated liver injury. Here, we identiﬁed CD59, as a novel HBc-interacting protein in hepa-
tocytes by tandem afﬁnity puriﬁcation (TAP) screening. The expression of CD59 wasmarkedly down-
regulated in HBc-transfected HepG2 or HepG2.215 cells, which resulted in an upshift of hepatocyte
sensitivity to membrane attack complex (MAC)-induced cell lysis. These results were consistent with
the accumulation of MACs in the liver of HBV-infected patients. Additional analyses using laser con-
focal microscopy, quantitative PCR and ﬂow cytometry revealed that CD59 was speciﬁcally translo-
cated to the nucleus upon binding to HBc, which induced the down-regulation of CD59 on both the
mRNA and protein levels.
Structured summary of protein interactions:
HBcphysically interacts with CD59 by anti bait coimmunoprecipitation (1, 2)
CD59 and HBccolocalize by confocal microscopy (View interaction)
HBcphysically interacts with OBFC1, TPM1 and CD59 by tandem afﬁnity puriﬁcation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction associated liver pathogenesis, but mechanisms underlying theHepatitis B virus (HBV) is a leading cause of chronic liver dis-
ease and death worldwide. Although HBV has been thought to be
a non-cytopathogenic virus, host immune responses induced by
viral persistence are largely responsible for disease progression
in chronically infected HBV patients [1]. The inﬂammatory cells,
in particular those playing essential roles in innate immunity,
such as natural killer cells, neutrophils, dendritic cells and macro-
phages, have been observed in the impaired regions of chronic
hepatitis B patients’ liver [2–4]. Consistently, a HBV transgenic
mouse model has further demonstrated that non-virus-speciﬁc
lymphocytes can exacerbate liver inﬂammation [5]. A recent
study has reported an inverse correlation between the comple-
ment protein (C4) in the peripheral blood and the extent of path-
ological liver impairment in patients carrying HBV, which
indicates that membrane attack complexes (MACs) are likely
involved in this process [6]. All of these ﬁndings suggest that
the innate immune system may play an important role in HBV-inﬂammation associated with the innate immune response re-
main to be elucidated.
Hepatitis B core antigen (HBc), the major viral capsid protein,
has been detected in the nuclear, cytoplasmic and membranous
compartments of HBV-infected hepatocytes [7–10]. Subsequent
studies have revealed pleiotropic functions of HBc that affect host
processes, for example, a recent study showed that HBc induced
expression proﬁle change of toll like receptor 2 (TLR2), an innate
immune protein, in HBV-infected hepatocytes [11]. HBc was also
shown to repress the expression of some genes [12–14]. These evi-
dence lines demonstrate that HBc can affect the physiological func-
tions of HBV-infected hepatocytes.
Despite extensive studies on HBV-induced hepatic inﬂamma-
tion, little is known about the roles played by HBc in this pro-
cess due to meager information regarding its interactions with
host proteins. Nonetheless, emerging evidence has revealed that
viral structural proteins may be essential factors for viral path-
ogenesis [15–17]. A good example is the core protein from hu-
man hepatitis C virus, which has been shown to be involved in
apoptosis, immunomodulation, oxidative stress, carcinogenesis
and other processes through interactions with host proteins
during viral infection [18–21]. In this study, a key regulatory
protein in the human complement system, CD59, was identiﬁed
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serving as the bait. Further studies have proven that the HBc–
CD59 interaction might play an important role in MAC assembly
and inﬂammation triggered by the complement system. The po-
tential mechanism of HBc-induced CD59 modulation was also
investigated in our work.
2. Materials and methods
2.1. Plasmids and cell lines
The pMSCV-HBc, pcDNA3.1-HBc and pcDNA3.1-CD59 vectors
were constructed respectively. All primers and methods used in
plasmid construction are listed in the Supplementary materials
and methods. Human hematomas cell lines, HepG2, and normal li-
ver cell lines, L02, were used for transfection in this study, with
HepG2.215 cell lines (stably transfected cell lines containing HBV
genome on a plasmid) as the control. All plasmid transfections
were performed using Lipofectamine™ 2000 reagent (Invitrogen)
and following the manufacturer’s instructions.
2.2. Tandem afﬁnity puriﬁcation (TAP)
See Supplementary materials and methods.
2.3. Co-immunoprecipitation assay
HepG2 cells stably expressing HBc were lysed in the radio
immunoprecipitation assay (RIPA) buffer, and soluble proteins
were collected after centrifugation at 10000g for 10 min. The
supernatant containing approximately 100 lg protein was pre-
cleared with normal IgG and Protein G conjugated on agarose
beads (Invitrogen) before incubation with new beads and mouse
monoclonal anti-HBc (Abcam, UK) overnight at 4 C on a rocker.
Beads were washed 4 times with the RIPA buffer and boiled in
the SDS loading buffer containing dithiothreitol for reducing
SDS–PAGE and western blot analysis.
2.4. Liver biopsies
Liver biopsies were extracted from 15 mild, 21 mid, 15 severe
chronic hepatitis patients and 10 healthy individuals. All patients
were diagnosed according to previously described criteria [22,23]
and had not received antiviral therapy within latest 6 months be-
fore sampling for this study. The experimental protocol was ap-
proved by the ethics committee of our university, and each
patient or healthy person provided consent.
2.5. Immunohistochemical analysis, Western blotting, ELISA,
quantitative PCR, Flow cytometry and complement lysis assay
See Supplementary materials and methods.
2.6. Confocal microscopy
HepG2 cells, HepG2-HBc, HepG2-NLS-CD59 and HepG2.215
were stained with the anti-HBc and/or the anti-CD59 antibodies
(1 mg/ml, 1:100, Abcam, UK) and observed by confocal micros-
copy. Details of the confocal microscopy protocol have been de-
scribed previously [24].Fig. 1. HBc interacts and colocalizes with CD59. (A) A schematic drawing of the
construct used in TAP screening. (B) SDS–PAGE and silver-staining of puriﬁed
protein complexes on a Bio-Rad 10% Ready Gel. Lane 1, protein standards; lane 2,
proteins from HepG2 cells transfected with pMSCV; and lane 3, proteins from cells
transfected with pMSCV-HBc. (C) Co-IP experiments with anti-HBc or anti-CD59
antibodies as the primary antibody, respectively. Cells that were not transfected or
transfected with pCDNA3.1 only were used as controls.2.7. Statistical analysis
The quantitative data were statistically analyzed by t-tests with
P < 0.05 deﬁned as the threshold of statistical signiﬁcance. Allanalyses were performed using the statistical program GraphPad
Prism 5 (GraphPad Software, Inc.).
3. Results
3.1. In vivo interaction between HBc and CD59
A pMSCV-HBc vector expressing HBc as the bait protein was
constructed to search for HBc-interacting proteins in stably trans-
fected HepG2 cells. The expressed product contains a biotinylated
tag to the N-terminus of HBc, and a removable protein A tag to its
C-terminus following a TEV cleavage site (Fig. 1A). After cell har-
vest and lysis, TAP was utilized to purify the potential HBc com-
plexes formed in transfected HepG2 cells. In contrast to the
control, SDS gel electrophoresis revealed multiple protein bands
in samples from the cells expressing HBc (Fig. 1B), indicating co-
puriﬁcation of a number of host proteins with HBc. All visible
bands were cut out from the gel and subjected to mass spectromet-
ric analysis, which revealed the presence of proteins including
OBFC1, WNT88, TPM1 and CD59. CD59, a MAC-related regulatory
protein, is the only protein of the identiﬁed HBc-interacting part-
ners involved in the innate immune system. Therefore, we focused
the following studies on this protein.
To verify the interaction between HBc and CD59, a co-immuno-
precipitation (Co-IP) assay was performed in HepG2 cells transfec-
ted with the pcDNA3.1-HBc vector. The protein complexes
between HBc and CD59 were captured using speciﬁc antibody
against HBc or CD59, respectively. Both proteins were clearly de-
tected by western blot analyses when speciﬁc antibodies against
them were separately used as the primary antibodies (Fig. 1C).
These data suggested the formation of a protein complex involving
these two proteins in transfected HepG2 cells.
3.2. HBc-induced down-regulation of CD59
To understand the consequence of the in vivo interaction
between HBc and CD59, the protein levels of CD59 on the cell
Fig. 3. HBc sensitizes hepatocytes to complement-mediated lysis. HepG2 (A) and
L02 (B) cells transfected with either the HBc expression construct (j) or an empty
vector (d) were tested for their sensitivity to complement-dependent cytotoxicity
triggered by anti-HBc mAb. Lysis assays in which both cell lines (HBc,N; empty
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the HepG2 cells, the ﬂuorescence intensity of CD59 on the surface
of the HepG2.215 cells and the HBc-transfected HepG2 cells was
clearly reduced (Fig. 2A), indicating that CD59 modulation on the
cell membrane was most likely driven by HBc transfection. To ex-
plore the reason for the modulation of CD59 levels on the cell
membrane, quantitative PCR and western blot experiments were
performed to detect the CD59 expression proﬁle. Compared with
the control, the mRNA levels of CD59 decreased by approximately
46% (P < 0.05) in the HBc-stable hepatocytes and by 67% (P < 0.001)
in the HepG2.215 cells (Fig. 2B). Consistently, western blot analysis
using ImageJ soft (NIH, USA) revealed that the CD59 protein levels
also decreased by approximately 50% and 35% in these cells
(Fig. 2C). These results indicated a marked reduction in the expres-
sion of CD59 at both the mRNA and protein levels, which likely ac-
counts for the reduction in CD59 on the cell membrane.
3.3. Down-regulation of CD59 sensitizes hepatocytes
to complement-mediated lysis
A complement lysis assay was carried out to detect the effect of
HBc-dependent CD59 down-regulation on complement-mediated
cytolysis. Different concentrations of healthy human serum were
used as the source of complement in this experiment. The results
revealed that HBc-transfected hepatocytes were more susceptible
than the control to complement-dependent killing at all serum
concentrations (Fig. 3). To demonstrate that the reduced expres-
sion of CD59 was sufﬁcient for the observed sensitization to com-
plement-dependent cytolysis, anti-CD59 Fab fragment was added
to the cell culture media to inhibit CD59’s anti-MAC activity. InFig. 2. Expression proﬁle of CD59 in HBc-transfected HepG2 cells and HepG2.215
cells. (A) The expression of CD59 on the membrane of hepatocytes was detected by
ﬂow cytometry. Histograms show the distribution of CD59 ﬂuorescence intensity
for HepG2-HBc cells (curve a), non-transfected HepG2 cells (curve b) and
HepG2.215 (curve c). PE, Phycoerythrin. (B) Relative mRNA levels of CD59
normalized to GAPDH in HepG2 cells 24 h after transfection with pCDNA3.1-HBc
and HepG2.215 cells. Non-transfected HepG2 Cells were used as the control. Data
are presented as the means ± S.E. of triplicate experiments. ⁄P < 0.05, ⁄⁄⁄P < 0.001.
(C) Comparison of HBc and CD59 protein levels in HepG2 cells 24 h post-
transfection with pCDNA3.1-HBc and HepG2.215 cells. GAPDH is presented as the
positive control.
vector,.) were pre-incubated with CD59-blocking Fab fragment were performed as
the controls. L02 cells were used as controls.parallel, empty vector-transfected cells in the absence of anti-
CD59 Fab were used as the negative control, while the same cells
in the presence of anti-CD59 Fab were used as the positive control.
As depicted in Fig. 3, the lytic susceptibility was increased after
blocking CD59 in both the cell line transfected with HBc and the
cell line transfected with the empty vector, conﬁrming that the re-
duced CD59 expression level resulted in the increased susceptibil-
ity of HBc-transfected hepatocytes to complement-mediated lysis.
3.4. CD59 down-regulation is associated with the accumulation
of MACs in the liver of HBV patients
Liver biopsies were obtained from a total of 51 chronic hepatitis
patients and 10 healthy individuals. The distribution of intrahe-
patic MACs and HBc were visualized on liver biopsies using immu-
nohistochemical staining. MACs and HBc accumulated on
hepatocytes from patients but not on hepatocytes from healthy
individuals; more signiﬁcantly, the extent of MAC and HBc in-
creased with the severity of hepatic impairment (Fig. 4A, B and
F). Subsequently, the expression proﬁle of CD59 in the tested sub-
jects was detected by quantitative PCR. Within our expectations,
the CD59 expression level was decreased in livers with a more se-
vere pathological status (Fig. 4C). In addition, the levels of periph-
eral C3 and C4 were measured in these samples. Compared to the
healthy references, the quantity of complement C4 was signiﬁ-
cantly reduced in the HBV-infected patients, whereas C3 exhibited
statistically insufﬁcient variation among the test groups (Fig. 4D
and E). These ﬁndings indicated that more C4 was consumed dur-
ing MAC formation. Taken together, these results suggest a strong
positive correlation between CD59 down-regulation and MAC-
dependent cytotoxicity in not only HBc-transfected HepG2 cells
but also the livers of HBV-infected patients.
Fig. 4. Detection of complement-related molecules and HBcAg in HBV-infected patients and healthy individuals. (A) Photomicrographs displaying immunohistochemically
stained MACs in liver biopsy specimens (20). Immunopositivity is highlighted with black arrows. HS: healthy subjects, CMLH: chronic mild hepatitis, CMDH: chronic mid-
degree hepatitis, CSH: chronic severe hepatitis. (B) Comparison between the degree of MAC accumulation and the histopathologic grade of HBV-infected patients’ livers. The
MAC amount was semiquantitatively estimated in formalin-ﬁxed, parafﬁn-embedded tissue specimens on the basis of the percentage of immunohistochemically stained
hepatocytes and the staining intensity (immunoreactive score, IRS). The grade was assessed according to the Lok and Scotto score [22,23]. The differences in MAC
accumulation between the grades of histologic differentiation are statistically signiﬁcant (P < 0.001). (C) Relative mRNA levels of CD59 normalized to GAPDH in various liver
biopsies. Healthy subjects were used as controls. Data are presented as the mean ± S.E. of triplicate experiments. (⁄P < 0.02, ⁄⁄P < 0.002, ⁄⁄⁄P < 0.002). (D and E) Contents of C3
and C4 in the peripheral blood of HBV-infected patients and healthy subjects detected by enzyme-linked immunosorbent assay (ELISA). ⁄P < 0.02, ⁄⁄⁄P < 0.001. (F) Relative
mRNA levels of HBcAg normalized to GAPDH in various liver biopsies. Data are presented as the mean ± S.E. of triplicate experiments. (⁄⁄⁄P < 0.002).
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To elucidate the mechanism of HBc-induced CD59 down-regu-
lation, the cellular location of CD59 in HepG2, HBc-transfected
HepG2 and HepG2.215 cells was examined by laser confocal
microscopy. The microscopy images showed that the bulk of the
CD59 molecules were located in the nuclei of the HBc-stable hepa-
tocytes and the HepG2.215 cells (Fig. 5, rows 2 and 3), but not in
the nuclei of non-transfected HepG2 cells (Fig. 5, row 1). Theseresults demonstrated that CD59 very likely bound to HBc in the
transfected hepatocytes and was hijacked into the nucleus by HBc.
The down-regulation and nuclear localization of CD59 in HBc-
transfected hepatocytes are reminiscent of the negative feedback
regulation of many cellular proteins, such as transforming growth
factor-b (TGF-b) and Wnt [25,26]. To test whether a similar nega-
tive feedback mechanism exists for CD59, three tandem nuclear
localization signals (NLSs) were added at the 50-end of the nucleo-
tide sequence encoding mature CD59 in a pcDNA3.1 vector, which
Fig. 5. Cellular localization of HBc and CD59 in hepatocytes detected by laser confocal microscopy. HepG2 cells transfected with pCDNA3.1-HBc and HepG2.215 cells were
stained with HBc antibody and CD59 antibody and visualized by confocal microscopy 24 h after transfection. HepG2 cells were used as controls. Color index: ﬂuorescein
isothiocyanate (FITC) in green, Alexa Fluor 647 in red, and cell nuclei stained by DAPI in blue. Scale bars: 10 lm.
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ing the NLSs was expressed and mostly localized to the nuclei of
these cells (Fig. 6A).
Quantitative PCR and ﬂow cytometry were performed to com-
pare the NLS-CD59 and endogenous CD59 in HepG2 cells. Two spe-
ciﬁc 50 primers were designed corresponding to the nucleotideFig. 6. Expression proﬁle of endogenous CD59 in NLS-CD59-transfected HepG2
cells (A) HepG2 cells transfected with pCDNA3.1-NLS-CD59 were stained with HBc
and CD59 antibodies and visualized by confocal microscopy 24 h after transfection.
Scale bars: 10 lm. (B) Relative mRNA levels of CD59 normalized to GAPDH in
HepG2 cells 24 h post-transfection with pCDNA3.1-NLS-CD59 that express NLS-
CD59. Non-transfected and pCDNA3.1-transfected HepG2 cells were used as
controls. Data are presented as the means ± S.E. of triplicate experiments.
⁄⁄P < 0.002. (C) The expression of CD59 on the membranes of hepatocytes was
detected by ﬂow cytometry. Histograms show the distribution of CD59 ﬂuorescence
intensity for HepG2 cells transfected with pCDNA3.1-NLS-CD59 (curve a) and non-
transfected HepG2 cells (curve b).sequence encoding the native signal peptide of CD59 and NLS.
The results showed that the expression levels of endogenous
CD59 in the HepG2 cells expressing NLS-CD59 were markedly de-
creased compared to those in the reference cells without exoge-
nous CD59 (Fig. 6B). Furthermore, ﬂow cytometry analysis
provided consistent results, indicating a signiﬁcant difference in
the amount of mature CD59 localized to the cell membrane be-
tween the two cell lines (Fig. 6C). This ﬁnding indicates that the
expression of CD59 is likely regulated by a negative feedback
mechanism.
4. Discussion
As the major capsid protein of HBV, HBc is not only a viral anti-
gen triggering an early host immune response including antibody
production [27], but also an active protein displaying pleiotropic
functions in host cells, likely through interactions with host DNA
or proteins [28]. However, the pathological roles played by HBc
in the innate immunity have not been thoroughly studied and
many questions remain unanswered. The potential interacting pro-
teins of HBc were poorly identiﬁed, leading to insufﬁcient mecha-
nistic understanding of the hepatic inﬂammation induced by HBV
infection. Here we demonstrate that HBc interacts with CD59, a
membrane molecule related with the complement system, down-
regulates its expression, increases the susceptibility of hepatocytes
to complement-mediated lysis and ﬁnally boosts liver damage dur-
ing chronic HBV infection. This example indicates that HBc can
modulate host gene expression by binding with host proteins,
which agrees with previous studies showing that viral nucleopro-
teins may interact with host proteins and regulate the expression
of both their own genes and those encoding downstream proteins
in the same regulatory pathways.
CD59, an important inhibitor of the complement system, is a
glycoprotein mostly anchored at the cell membrane via binding
with glycosyl-phosphatidyl inositol, although soluble monomer
also exists in the cytoplasm [29–31], which agrees with our stain-
ing results shown in Fig. 5. Our experimental results clearly
revealed downshifted expression of CD59 in HBc-transfected
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showing decreased expression level of CD59 in two HBV-transfec-
ted hepatocyte cell lines [32]. Previous studies have shown that the
reduced expression of CD59 contributes to MAC assembly at the
cell membrane, thereby leading to cellular injury [33]. Further-
more, the data shown here indicate that HBc down-regulates the
expression of CD59 by hijacking it from the cytoplasm to the nu-
cleus in HBc-transfected HepG2 and HepG2.215 cells. The translo-
cation of host proteins via HBc binding has been observed in other
laboratories. For example, HBc interacts with the central domain of
myxovirus resistance gene A (MxA) in HBc-transfected hepato-
cytes, and causes accumulation of the MxA protein in perinuclear
compartments [24].
In this study, the nuclear localization of CD59, which had been
never observed previously, was clearly visualized in HBc-transfec-
ted HepG2 cells by confocal microscopy (Figs. 1 and 5). This obser-
vation, as well as the evidence obtained from the control
experiment using NLS-CD59 as the reference molecule, undoubt-
edly indicates the translocation of CD59 to the nucleus upon bind-
ing with HBc. As a result, the CD59 concentration in the nucleus
may rise to a higher level than normal (Fig. 5), which could in turn
inhibit its own gene expression. Similar negative feedback loops
have been observed for many prokaryotic and eukaryotic proteins,
e.g., TGF-b and Wnt [25,26].
Regarding the accumulation of MACs in the liver and the de-
creased level of C4 in peripheral blood observed in HBV patients,
the data shown in Fig. 4 suggest that the down-regulated expres-
sion of CD59 promotes complement-mediated lysis and exacer-
bates liver injury in those patients. HBV-speciﬁc T cells have
been considered to play important roles in inducing hepatocellular
damage during chronic HBV infection [34–36]. However, many
pieces of recent evidence have hinted that the persistent inﬂam-
mation induced by HBV infection was more likely caused by inﬁl-
tration of non-virus-speciﬁc lymphocytes and cytokines in the liver
and is closely related with the innate immune system [2–4]. Accor-
dantly, our results demonstrate the involvement of the comple-
ment system in hepatic inﬂammation, highlighting the possible
roles of innate immunity in the process of HBV infection. As a di-
rect consequence of CD59 down-regulation at the RNA level, the
density of this regulatory protein on the cell membrane decreases
dramatically (Fig. 2A), which allows increased deposition of MACs
and stimulates the subsequent complement-mediated necrosis.
Cell lysis leads to cellular perforation and the bulky release of cel-
lular contents, including danger signal molecules, such as danger-
associated molecular patterns (DAMPs) [37,38]. These endogenous
DAMPs could function as strong chemokines that recruit a number
of inﬂammatory cells and cytokines, resulting in deeper inﬂamma-
tory injuries [39]. Conversely, tumor cells can effectively inhibit at-
tacks from the complement system by enhancing the expression of
CD59 at the cell surface [40]. Based on our ﬁndings, the inhibition
of the HBc-CD59 interaction may prevent the occurrence or devel-
opment of inﬂammatory liver diseases caused by HBV infection,
and accordingly, factors that block this process could be potential
drug candidates for ﬁghting these diseases.
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